164 related articles for article (PubMed ID: 15828852)
1. Pharmacokinetics of famotidine in infants.
Wenning LA; Murphy MG; James LP; Blumer JL; Marshall JD; Baier J; Scheimann AO; Panebianco DL; Zhong L; Eisenhandler R; Yeh KC; Kearns GL
Clin Pharmacokinet; 2005; 44(4):395-406. PubMed ID: 15828852
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of famotidine in patients with cystic fibrosis.
Maish WA; McCubbin MM; Letzig LG; Farrar HC; Kearns GL
J Clin Pharmacol; 1998 Nov; 38(11):1010-6. PubMed ID: 9824781
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of famotidine in paediatric patients.
James LP; Kearns GL
Clin Pharmacokinet; 1996 Aug; 31(2):103-10. PubMed ID: 8853932
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacodynamics of famotidine in infants.
James LP; Marotti T; Stowe CD; Farrar HC; Taylor BJ; Kearns GL
J Clin Pharmacol; 1998 Dec; 38(12):1089-95. PubMed ID: 11301560
[TBL] [Abstract][Full Text] [Related]
5. Famotidine pharmacokinetics following oral and intravenous administration in patients with liver disease: results of a preliminary study.
Morgan MY; Stambuk D
Postgrad Med J; 1986; 62 Suppl 2():29-37. PubMed ID: 2890149
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.
Hatlebakk JG; Berstad A
Clin Pharmacokinet; 1996 Nov; 31(5):386-406. PubMed ID: 9118586
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and pharmacodynamics of famotidine in children.
James LP; Marshall JD; Heulitt MJ; Wells TG; Letzig L; Kearns GL
J Clin Pharmacol; 1996 Jan; 36(1):48-54. PubMed ID: 8932543
[TBL] [Abstract][Full Text] [Related]
8. Developmental pharmacokinetics and pharmacodynamics of nizatidine.
Abdel-Rahman SM; Johnson FK; Connor JD; Staiano A; Dupont C; Tolia V; Winter H; Gauthier-Dubois G; Kearns GL
J Pediatr Gastroenterol Nutr; 2004 Apr; 38(4):442-51. PubMed ID: 15085026
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of famotidine in children with gastroduodenal ulcers.
Nagita A; Manago M; Aoki S; Mino M; Suzuki K; Ashida K
Ther Drug Monit; 1994 Oct; 16(5):444-9. PubMed ID: 7846741
[TBL] [Abstract][Full Text] [Related]
10. Age-dependent pharmacokinetics of lansoprazole in neonates and infants.
Zhang W; Kukulka M; Witt G; Sutkowski-Markmann D; North J; Atkinson S
Paediatr Drugs; 2008; 10(4):265-74. PubMed ID: 18590345
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and efficacy of intravenous famotidine in adult cattle.
Balcomb CC; Heller MC; Chigerwe M; Knych HK; Meyer AM
J Vet Intern Med; 2018 May; 32(3):1283-1289. PubMed ID: 29572958
[TBL] [Abstract][Full Text] [Related]
12. Single-dose pharmacokinetics and bioavailability of famotidine in man. Results of multicenter collaborative studies.
Yeh KC; Chremos AN; Lin JH; Constanzer ML; Kanovsky SM; Hucker HB; Antonello J; Vlasses P; Ryan JR; Williams RL
Biopharm Drug Dispos; 1987; 8(6):549-60. PubMed ID: 2892544
[TBL] [Abstract][Full Text] [Related]
13. Phase I, multicenter, randomized, open-label study evaluating the pharmacokinetics and safety profile of repeated once-daily doses of intravenous esomeprazole in children 0 to 17 years of age.
Sandström M; Davidson G; Tolia V; Sullivan JE; Långström G; Lundborg P; Brown K
Clin Ther; 2012 Aug; 34(8):1828-38. PubMed ID: 22832034
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of famotidine and ranitidine in critically ill children.
Madani S; Kauffman R; Simpson P; Lehr VT; Lai ML; Sarniak A; Tolia V
J Clin Pharmacol; 2014 Feb; 54(2):201-5. PubMed ID: 24258773
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of famotidine in man.
Kroemer H; Klotz U
Int J Clin Pharmacol Ther Toxicol; 1987 Aug; 25(8):458-63. PubMed ID: 2888738
[TBL] [Abstract][Full Text] [Related]
16. Famotidine for infant gastro-oesophageal reflux: a multi-centre, randomized, placebo-controlled, withdrawal trial.
Orenstein SR; Shalaby TM; Devandry SN; Liacouras CA; Czinn SJ; Dice JE; Simon TJ; Ahrens SP; Stauffer LA
Aliment Pharmacol Ther; 2003 May; 17(9):1097-107. PubMed ID: 12752346
[TBL] [Abstract][Full Text] [Related]
17. Effects of age and chronic renal failure on the urinary excretion kinetics of famotidine in man.
Lin JH; Chremos AN; Yeh KC; Antonello J; Hessey GA
Eur J Clin Pharmacol; 1988; 34(1):41-6. PubMed ID: 2896129
[TBL] [Abstract][Full Text] [Related]
18. Famotidine disposition in children and adolescents with chronic renal insufficiency.
Maples HD; James LP; Stowe CD; Jones DP; Hak EB; Blumer JL; Vogt B; Wilson JT; Kearns GL; Wells TG;
J Clin Pharmacol; 2003 Jan; 43(1):7-14. PubMed ID: 12520622
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of famotidine in patients with cirrhosis and ascites.
Vinçon G; Baldit C; Couzigou P; Demotes-Mainard F; Elouaer-Blanc L; Bannwarth B; Begaud B
Eur J Clin Pharmacol; 1992; 43(5):559-62. PubMed ID: 1483496
[TBL] [Abstract][Full Text] [Related]
20. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
